(ZTS) Zoetis - Overview
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NYSE (USA) | Market Cap: 51.975m USD | Total Return: -20.7% in 12m
Medicines, Vaccines, Diagnostics, Biodevices, Genetics
Total Rating 47
Safety 88
Buy Signal -0.09
Drug Manufacturers - Specialty & Generic
Industry Rotation: -1.9
Industry Rotation: -1.9
Market Cap:
52.0B
Avg Turnover: 421M USD
Avg Turnover: 421M USD
ATR:
2.61%
Peers RS (IBD): 19.1
Peers RS (IBD): 19.1
Risk 5d forecast
Volatility25.0%
Rel. Tail Risk-4.27%
Reward TTM
Sharpe Ratio-0.61
Alpha-33.71
Character TTM
Beta0.346
Beta Downside0.379
Drawdowns 3y
Max DD41.87%
CAGR/Max DD-0.25
EPS (Earnings per Share)
EPS CAGR: -45.34%
EPS Trend: -16.5%
EPS Trend: -16.5%
Last SUE: -4.00
Qual. Beats: 0
Qual. Beats: 0
Revenue
Rev. CAGR: 5.03%
Rev. Trend: 91.4%
Rev. Trend: 91.4%
Last SUE: 0.76
Qual. Beats: 0
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Description: ZTS Zoetis
Zoetis Inc. (ZTS) develops and commercializes animal health products globally. This includes medicines, vaccines, diagnostics, and precision health solutions.
The company serves both companion animals (dogs, cats, horses) and livestock (cattle, swine, poultry, fish, sheep). The animal health sector is a specialized area within pharmaceuticals, focusing on species-specific biological and chemical products.
Product categories include parasiticides, vaccines, dermatology, anti-infectives, and pain management. Zoetis also offers diagnostic tools like point-of-care products and reference laboratory services. The business model involves direct sales to veterinarians, livestock producers, and pet owners.
The company engages in strategic collaborations, such as with Blacksmith Medicines, Inc. for antibiotic discovery. For further in-depth analysis of Zoetiss financial performance and market position, consider exploring ValueRay.
- Companion animal product sales drive revenue growth
- Livestock product demand impacts international sales
- Research and development pipeline success is crucial
- Regulatory approvals affect product commercialization
Piotroski VR‑10 (Strict)
6.5
| Net Income: 2.67b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.15 > 0.02 and ΔFCF/TA -1.38 > 1.0 |
| NWC/Revenue: 47.88% < 20% (prev 27.81%; Δ 20.07% < -1%) |
| CFO/TA 0.19 > 3% & CFO 2.90b > Net Income 2.67b |
| Net Debt (7.18b) to EBITDA (4.09b): 1.76 < 3 |
| Current Ratio: 3.03 > 1.5 & < 3 |
| Outstanding Shares: last quarter (438.6m) vs 12m ago -2.77% < -2% |
| Gross Margin: 70.49% > 18% (prev 0.69%; Δ 6.98k% > 0.5%) |
| Asset Turnover: 63.74% > 50% (prev 65.01%; Δ -1.27% > 0%) |
| Interest Coverage Ratio: 15.13 > 6 (EBITDA TTM 4.09b / Interest Expense TTM 238.0m) |
Altman Z''
7.57
| A: 0.29 (Total Current Assets 6.77b - Total Current Liabilities 2.23b) / Total Assets 15.47b |
| B: 0.89 (Retained Earnings 13.74b / Total Assets 15.47b) |
| C: 0.24 (EBIT TTM 3.60b / Avg Total Assets 14.85b) |
| D: 1.06 (Book Value of Equity 12.91b / Total Liabilities 12.14b) |
| Altman-Z'' Score: 7.57 = AAA |
Beneish M
-2.93
| DSRI: 1.18 (Receivables 1.59b/1.32b, Revenue 9.47b/9.26b) |
| GMI: 0.98 (GM 70.49% / 69.10%) |
| AQI: 0.94 (AQ_t 0.31 / AQ_t-1 0.33) |
| SGI: 1.02 (Revenue 9.47b / 9.26b) |
| TATA: -0.01 (NI 2.67b - CFO 2.90b) / TA 15.47b) |
| Beneish M-Score: -2.93 (Cap -4..+1) = A |
What is the price of ZTS shares?
As of April 10, 2026, the stock is trading at USD 119.99 with a total of 1,683,272 shares traded.
Over the past week, the price has changed by +1.74%, over one month by -1.94%, over three months by -5.24% and over the past year by -20.72%.
Over the past week, the price has changed by +1.74%, over one month by -1.94%, over three months by -5.24% and over the past year by -20.72%.
Is ZTS a buy, sell or hold?
Zoetis has received a consensus analysts rating of 4.26.
Therefore, it is recommended to buy ZTS.
- StrongBuy: 10
- Buy: 4
- Hold: 5
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ZTS price?
| Analysts Target Price | 151 | 25.8% |
Zoetis (ZTS) - Fundamental Data Overview
as of 05 April 2026
P/E Trailing = 19.624 P/E Forward = 16.6945
P/S = 5.4902
P/B = 14.8638
P/EG = 1.8986
Revenue TTM = 9.47b USD
EBIT TTM = 3.60b USD
EBITDA TTM = 4.09b USD
Long Term Debt = 9.04b USD (from longTermDebt, last quarter)
Short Term Debt = 53.0m USD (from shortTermDebt, last quarter)
Debt = 9.49b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.18b USD (from netDebt column, last quarter)
Enterprise Value = 59.16b USD (51.98b + Debt 9.49b - CCE 2.31b)
Interest Coverage Ratio = 15.13 (Ebit TTM 3.60b / Interest Expense TTM 238.0m)
EV/FCF = 25.91x (Enterprise Value 59.16b / FCF TTM 2.28b)
FCF Yield = 3.86% (FCF TTM 2.28b / Enterprise Value 59.16b)
FCF Margin = 24.12% (FCF TTM 2.28b / Revenue TTM 9.47b)
Net Margin = 28.23% (Net Income TTM 2.67b / Revenue TTM 9.47b)
Gross Margin = 70.49% ((Revenue TTM 9.47b - Cost of Revenue TTM 2.79b) / Revenue TTM)
Gross Margin QoQ = 68.87% (prev 70.21%)
Tobins Q-Ratio = 3.82 (Enterprise Value 59.16b / Total Assets 15.47b)
Interest Expense / Debt = 0.60% (Interest Expense 57.0m / Debt 9.49b)
Taxrate = 20.76% (158.0m / 761.0m)
NOPAT = 2.85b (EBIT 3.60b * (1 - 20.76%))
Current Ratio = 3.03 (Total Current Assets 6.77b / Total Current Liabilities 2.23b)
Debt / Equity = 2.85 (Debt 9.49b / totalStockholderEquity, last quarter 3.33b)
Debt / EBITDA = 1.76 (Net Debt 7.18b / EBITDA 4.09b)
Debt / FCF = 3.15 (Net Debt 7.18b / FCF TTM 2.28b)
Total Stockholder Equity = 4.59b (last 4 quarters mean from totalStockholderEquity)
RoA = 18.00% (Net Income 2.67b / Total Assets 15.47b)
RoE = 58.23% (Net Income TTM 2.67b / Total Stockholder Equity 4.59b)
RoCE = 26.41% (EBIT 3.60b / Capital Employed (Equity 4.59b + L.T.Debt 9.04b))
RoIC = 23.96% (NOPAT 2.85b / Invested Capital 11.91b)
WACC = 6.16% (E(51.98b)/V(61.47b) * Re(7.20%) + D(9.49b)/V(61.47b) * Rd(0.60%) * (1-Tc(0.21)))
Discount Rate = 7.20% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: -100.0 | Cagr: -2.36%
[DCF] Terminal Value 87.42% ; FCFF base≈2.29b ; Y1≈2.70b ; Y5≈4.13b
[DCF] Fair Price = 253.3 (EV 114.11b - Net Debt 7.18b = Equity 106.93b / Shares 422.1m; r=6.16% [WACC]; 5y FCF grow 18.89% → 3.0% )
EPS Correlation: -16.49 | EPS CAGR: -45.34% | SUE: -4.0 | # QB: 0
Revenue Correlation: 91.38 | Revenue CAGR: 5.03% | SUE: 0.76 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.90 | Chg7d=+0.000 | Chg30d=+0.003 | Revisions Net=+0 | Analysts=14
EPS current Year (2026-12-31): EPS=7.03 | Chg7d=+0.000 | Chg30d=-0.000 | Revisions Net=+1 | Growth EPS=+9.6% | Growth Revenue=+4.6%
EPS next Year (2027-12-31): EPS=7.54 | Chg7d=+0.000 | Chg30d=-0.034 | Revisions Net=+0 | Growth EPS=+7.4% | Growth Revenue=+5.0%
[Analyst] Revisions Ratio: +0.00 (1 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 2.8% (Discount Rate 7.9% - Earnings Yield 5.1%)
[Growth] Growth Spread = +1.2% (Analyst 4.1% - Implied 2.8%)
External Resources